Active Biotech's partner Teva comments on DEFINE study results in Multiple Sclerosis

April 26, 2011 07:00 (CEST)

Read Teva Pharmaceutical Industries Ltd's (NASDAQ: TEVA) complete press release here.


For further information on Active Biotech's and Teva's oral MS drug laquinimod, please visit or

Lund, April 26, 2011


Active Biotech AB (publ)


Tomas Leanderson
President & CEO




For further information, please contact:
Göran Forsberg
Vice President Investor Relations & Business Development
Tel +46 (0)46 19 11 54



Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDexTM for RA. Please visit  for more information.


Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00      


Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 26, 2011, at 07:00 a.m.                

Active Biotech’s partner Teva comments on DEFINE